Patheon Revenue and Competitors

Location

$200M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Patheon's total funding is $200M.

Employee Data

  • Patheon has 2546 Employees.(i)
  • Patheon grew their employee count by -3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4180M133206%$550M$18.5B
Add Company

Patheon is a leading global provider of contract dosage form development and manufacturing services to the pharmaceutical and biotechnology industries.Employing more than 4,700 highly-skilled staff, Patheon’s network of modern manufacturing facilities located in North America and Europe offer more than three million square feet (300,000 m2) of best in class capacity. With three facilities in the United States, three in Canada and four in Europe (including two in Italy, one in France and one in the United Kingdom) Patheon is able to meet the international requirements of its customers

keywords:N/A

$200M

Total Funding

2546

Number of Employees

N/A

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Patheon News

2022-04-17 - Bispecific Antibody Therapeutic Market Size, Share, Growth 2022 ... Blackswan Real Estate –

Bispecific Antibody Therapeutic Market Size, Share, Growth 2022 ... Blackswan Real Estate –

2022-04-17 - Pharmaceutical Intermediates Consumption Market Share 2022 ... The New York Irish Emgirant

Pharmaceutical Intermediates Consumption Market Share 2022 ... The New York Irish Emgirant

2022-04-17 - Global Pharmaceutical Intermediates Market 2022 Research ... Blackswan Real Estate –

Global Pharmaceutical Intermediates Market 2022 Research ... Blackswan Real Estate –

2012-02-17 - Contract drug manufacturer Patheon names former BCRX executive new CFO

Grant comes to Patheon as the company adjusts its business strategy. Last year, the company announced a new corporate strategy that would evaluate its global footprint and cut costs. Those changes included closing some facilities. Meanwhile, Patheon is putting additional emphasis on its pharmace ...

2011-10-20 - Patheon inks $18M deal with Boehringer on diabetes drugs in R&D

“I am very gratified that Boehringer Ingelheim recognizes our expertise in formulating, scaling and successfully launching complex formulations such as these molecules,” Patheon President of Pharmaceutical Development Services and Chief Scientific Officer Mark Kontny said in a prepared statement ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$715.5M28855%$1.8M
#2
$885.5M30128%N/A
#3
$726.1M318223%N/A
#4
$2150.3M4726-1%N/A
#5
$1201.8M47697%N/A